Matthias Cheung, PhD, Discusses Current Federal Legislation and Ongoing Policies Regarding Orphan Drugs and Rare Disease
Matthias Cheung, PhD, FCSHP, FASHP, a principal at Advanced Rx Consulting, LLC, and an adjunct professor of pharmacy practice at the University of the Pacific, Thomas J. Long School of Pharmacy and Health Services, discusses the circumstances and factors that catalyzed the passage of current legislation and regulatory policies for orphan drugs, rare diseases, and ultra-rare diseases.
This video was taken at the Academy of Managed Care Pharmacy's 25th Annual Meeting & Expo in San Diego, CA, on April 5, 2013.
Leading political outlets report today that shifts in public opinion on the Affordable Care Act (ACA), or at least its components, have led US Senate campaigns to adjust ads accordingly, most notably in Arkansas. However, the changes in tone toward the ACA, often called “Obamacare,” may not change the outcome of the 2014 mid-term elections, according to published reports.
Peter Paul Yu, MD, FASCO, who this summer became president of the American Society of Clinical Oncology, shared how the group is leading the discussion of what constitutes value in cancer care, as well as the need to engage all stakeholders in this critical topic.
A century ago, employee health and well-being was of such little concern to most US employers that it took the passage of workers’ compensation laws for most to care, because suddenly it affected the bottom line.
Insurers are trapped between pharmaceutical companies developing increasingly expensive drug treatments, and states that want to reduce the patient-burden of co-pays. Additionally, states like New York and Alaska have banned payers from using specialty formularies.